Erin Hofstatter, MD

Dr. Hofstatter serves as an academic breast cancer medical oncologist and Co-Director of the Smilow Cancer Genetics and Prevention Program at Yale, with a clinical specialty and research interest in breast cancer risk. Her clinical work includes seeing patients with breast cancer as well as patients at high risk of breast cancer due to a genetic mutation or other strong risk profile. Thus, her clinical work directly informs and inspires her research in breast cancer treatment and prevention. Since taking on the role of Co-Director of the Cancer Genetics and Prevention Program in 2014, she has successfully grown the clinical genetic counseling service to serve over 2000 patients per year, at multiple sites throughout the state of Connecticut. She has developed a robust clinical program that blends the services of genetic counselors and physicians, and has built a collaborative research program including a rich biorepository. In addition, Dr. Hofstatter serves as the Principal Investigator of several national cooperative group trials, including several trials for BRCA+ breast cancer, as well as her own investigator-initiated trials in DCIS and triple-negative breast cancer. She has developed skills in clinical trial design, survey development, epidemiology and biostatistics through her training and academic practice. Furthermore, Dr. Hofstatter has also developed skills in translational research, serving as Principal Investigator on a study examining epigenetic signatures of breast cancer risk and measures of aging in normal breast tissue.clinical breast cancer genetics